← Research library

Thymopentin for allergy symptoms — EP0235904A2

Patent disclosure · 1987

What the patent describes
30 participants randomized, 10 per arm, in a double-blind, double-dummy comparison. Thymopentin 50 mg subcutaneously three times weekly, thymopentin 100 mg intravenously once weekly, or matching placebo injections for 12 weeks. Table I uses ten weeks of symptom diaries.
Reported evidence
In the patent’s ragweed-allergy example, the mean weekly symptom count was 9.20 with IV thymopentin versus 19.22 with placebo. The subcutaneous comparison was statistically inconclusive.

Mean weekly symptom count, IV arm · 9.20 versus 19.22 with placebo (p=0.0145).

Reported patent results

Reported findings

In the patent’s ragweed-allergy example, the mean weekly symptom count was 9.20 with IV thymopentin versus 19.22 with placebo. The subcutaneous comparison was statistically inconclusive.

30 participants randomized, 10 per arm, in a double-blind, double-dummy comparison. Thymopentin 50 mg subcutaneously three times weekly, thymopentin 100 mg intravenously once weekly, or matching placebo injections for 12 weeks. Table I uses ten weeks of symptom diaries.

Population or model 30 participants randomized, 10 per arm, in a double-blind, double-dummy comparison. Thymopentin 50 mg subcutaneously three times weekly, thymopentin 100 mg intravenously once weekly, or matching placebo injections for 12 weeks. Table I uses ten weeks of symptom diaries.

Results · Original EP application and US family grant, phase-II example and Table I.
MeasureResultComparison, timing and statistics
Mean weekly symptom count, IV arm9.20 versus 19.22 with placebo (p=0.0145).
Mean weekly symptom count, subcutaneous arm12.84 versus 19.22 with placebo (p=0.1394).
Average weekly symptom counts from Table I
Average weekly symptom counts from Table I
Group (10 assigned each)MildSevereTotalTotal p vs placebo
50 mg subcutaneous10.202.6412.840.1394
100 mg intravenous7.431.779.200.0145
Placebo13.905.3219.22—

The small patent example uses self-reported symptoms and multiple comparisons. It gives no numerical adverse-event results for this example.

Source for these results ↗ · Reviewed 2026-11-14

Patent claims and provenance

Use. Claims use of thymopentin or a salt for allergy symptoms. The measured human example concerns ragweed allergic rhinitis.

The European and US texts describe the same 30-person trial. A 1986 conference abstract is cited in the family and may describe the same cohort.

Publication
EP0235904A2 ↗ · 1987-09-09
Earliest priority / filing
1986-01-24 / 1987-01-23
Original applicant / assignee
Ortho Pharmaceutical Corp
Indexed status
Withdrawn · checked 2026-11-14
Patent family
25236742 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Treatment of allergy with thymopentin

Inventors: Gideon Goldstein.

EP0235904A2 · EP0235904A3 · US4749690A

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • The European and US texts describe the same 30-person trial. A 1986 conference abstract is cited in the family and may describe the same cohort.
  • The small patent example uses self-reported symptoms and multiple comparisons. It gives no numerical adverse-event results for this example.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Related publications may describe some of the same participants or experiments.

Source details

Patent publication · Original patent text and indexed metadata

Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.

Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Sources checked

Citation

Published

Patent / reported experimentsFull text available

Gideon Goldstein. Thymopentin for allergy symptoms — EP0235904A2 EP0235904A2 · patent family 25236742

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards